Clinical Trials

The purpose of this study is to determine how common bariatric surgical procedures alter carbohydrate metabolism by examining the effect of vagal nerve stimulation on insulin secretion and action.

The purpose of this study is to evaluate the impact of vagal nerve stimulation on symptom burden, neuroinflammatory change, and blood markers of inflammation in patients with post COVID syndrome who have fatigue and headache.

The purpose of this study is to evaluate self-reported changes in sweating among patients who have undergone vagal nerve stimulation (VNS) between January 1, 2000, and December 31, 2024

This is a pivotal phase study of up to 120 subjects and 15 clinical sites. All subjects are implanted with the Vivistim System® and then randomized to either study treatment or active-control treatment. The randomization will be stratified by age (<30, >30) and baseline FMA UE (20 to <35; >35 to 50). Study treatment is vagus nerve stimulation (VNS) delivered during rehabilitation. Active control treatment is rehabilitation (standard-of-care treatment) with only a minimal amount of VNS at the start of each session intended to support blinding.

The purpose of this study is to measure the change in dizziness, as measured by change in Dizziness Handicap Inventory (DHI) score, following a 4-week treatment period with aurical transcutaneous vagus nerve stimulation (aTVNS).

The purpose of this study is to delineate the neural mechanisms of VNS-REHAB (Vagus Nerve Stimulation paired with task-specific upper limb rehabilitation).

The purpose of this study is to investigate whether VNS therapy leads to any changes in the cognitive functions of individuals who have survived a stroke.

The purpose of this study is to evaluate the safety, feasibility, and efficacy of vagus nerve stimulation (VNS) paired with mobility training to improve lower extremity function and gait in individuals with chronic ischemic stroke.